---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066419"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:25:37.113353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg

## Summary
- Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.
- Cash and marketable securities $97.8M as of March 31, 2025; runway at least 12 months.
- Positive DM1 data: mean splicing correction of 29.1% 28 days after single 10 mg/kg dose of PGN-EDODM1.
- CONNECT1-EDO51 10 mg/kg dystrophin data expected Q3 2025; CONNECT2 trial voluntarily paused.
- Board added Lisa Wyman and Mitchell H. Finer, PhD in March 2025.

## SEC filing metadata
- accession: 0000950170-25-066419
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/0000950170-25-066419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/pepg-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066419
- JSON: https://secwatch.observer/filing/0000950170-25-066419.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.